Introduction
Children diagnosed with amplified musculoskeletal pain syndrome (AMPS) experience intense pain and functional disability without evidence of tissue damage. AMPS encompasses an array of pain syndromes, including complex regional pain syndrome (CRPS), fibromyalgia, and diffuse and localized musculoskeletal pain, which can be constant or intermittent [1] . The prevalence of pediatric AMPS is not well defined in childhood. It is estimated that 6-12% of children have fibromyalgia, and in 1996, 12% of children presenting to a rheumatologist had an idiopathic pain syndrome [2] [3] [4] [5] [6] . Patients typically see multiple physicians and medical specialists, and receive a number of diagnoses, before the condition is correctly identified. Many children with AMPS have attempted a variety of medications, procedures, and surgeries to diagnose or treat their pain. Nearly all treatments for chronic pain introduce the risk of iatrogenic complications and adverse events [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The prolonged search for effective treatment leaves these children vulnerable to medication overuse and numerous trips to the emergency department, all while burdening families with excessive healthcare costs.
The purpose of this study was to evaluate patients seen within our Amplified Musculoskeletal Pain Clinic over time to determine trends in medicalization.
Methods

Definition
Medicalization is defined here in terms of medication use and repeated exposure to a medical environment in the pursuit of a treatment or cure for pain, which may include seeing different professionals and undergoing procedures or surgeries [20] .
Participants
We included 899 consecutive, individual patients ages 3-20 who presented for an initial evaluation at a single tertiary pediatric pain clinic specializing in musculoskeletal pain between January 1, 2008, and December 31, 2014 and consented to be included in a descriptive, observational registry.
Study Design
A retrospective evaluation was conducted using selfreported data from patients diagnosed with AMPS who agreed to participate in a descriptive, observational registry. All patients who presented to clinic with amplified pain were approached and asked to participate in this registry; 98-99% agreed to participate. Information from those who agreed to participate was collected via the history of present illness section of the patient's electronic medical record. Patients and their parents provided assent and consent for this database and its corresponding data were queried for the descriptive study discussed here.
Institutional Review
The Committees for the Protection of Human Subjects granted waivers of consent and assent for this study because it was conducted using retrospective information from the database indicated above without specific patient identifiers.
Measures
Medicalization was operationally defined as the pursuit of a treatment or cure for pain, including both western medicine and alternative treatments. Variables used to capture the degree of medicalization included the total number of medications tried, procedures pursued, therapies tried, aids used, number of individual healthcare providers seen, hospitalizations, and surgeries performed, all prior to their visit. We counted each variable individually as a single occurrence. The number of visits to the same provider or duration of use was not measured. For example, six visits to an orthopedic surgeon and 20 visits to a physical therapist were each counted as one visit. In an effort to capture patients who saw a provider but later opted out of therapy, we counted the practitioner visit and corresponding therapy as separate variables. For example, a visit to a physical therapist and participation in physical therapy were analyzed as separate variables. The individual variables for each of these aspects of medicalization are shown in Table 1 .
The measures used to assess pain and functional status included patient report of pain on a 0-10 numerical rating scale (NRS) and the Functional Disability Inventory (FDI).
Measurement Scales
The patient numerical rating scale (NRS) is a patient report of pain on a 0-10 scale, where 0 indicates "no pain" and 10 indicates "worst imaginable pain."
Functional Disability Inventory (FDI)
The Functional Disability Inventory (FDI), a 15 item measure, assesses the impact of an adolescent's physical health on daily physical and psychosocial functioning using a 5-point scale. A score of 0 when considering a given task such as doing chores at home indicates "no trouble", while a score of 5 signifies an "impossible" task. A total score of 0-12 indicates no/minimal disability, 13-20 indicates mild disability, 21-29 indicates moderate disability, and a total score greater than 30 indicates severe disability. The FDI is a valid, reliable, and commonly used measure in the pediatric chronic pain population [21] .
Statistical Analysis
Subject characteristics are summarized by frequencies and percentages by year for categorical variables (e.g., race, sex, pain diagnosis), with Chi-square comparisons done between years to test for population differences by year. Continuous variables are reported by medians and interquartile range for continuous variables (e.g., age, pain duration, FDI), with Chi-Square comparisons to test for significant differences by year.
The mean medications tried, procedures, studies, professionals seen, therapies, aids, hospitalizations, and surgeries were compared by year using one-way ANOVAs with a Bonferroni correction to 0.007. Additionally, a post-hoc comparison was done for three medications to attempt to see if the significant increase in the use of medications could be attributed to them (pregabalin, duloxetine, and gabapentin).
All analyses were completed using SPSS Statistics version 23 (IBM, Armonk, NY).
Results Table 1 is a description of each individual variable used in the classification of medicalization. Subject data are summarized in Table 2 . The median pain score pain duration, and FDI did not change significantly by year, however, significantly more children have presented to clinic with diffuse pain in recent years (P < 0.001).
Trends in medicalization are shown in Table 3 , Table 4 , and Figure 1 . There has been a significant increase in patients' past medications, procedures, therapies, professionals seen, hospitalizations, and surgeries from 2008-2014 (each P < 0.001). The total use of aids has not significantly changed, as seen in Table 4 .
Patients who are currently on medications at the time of their initial visit have significantly increased since 2008 (P < 0.001). In order to look more closely at the increase in the average use of medications (past and current), comparisons were run by year for a selected subset of medications. Three medications-pregabalin, duloxetine, and gabapentin-were all analyzed by year. Pregabalin and duloxetine were selected due to their indication in adults with fibromyalgia. Gabapentin was selected because of its anecdotally frequent prescription by neurologists and pain specialists. A total of 261 subjects presented with previous exposure to gabapentin, 54 subjects had been prescribed duloxetine, and 73 subjects with exposure to pregabalin. Pregabalin was the only one of these agents to demonstrate a significant increase in use, rising from 4% to 18% (P < 0.01) between 2008 and 2014.
Discussion
We have previously argued that children with amplified musculoskeletal pain syndrome are effectively treated with intense physical therapy, occupational therapy, and psychotherapy [22] [23] [24] [25] . There are surprisingly few studies examining the effectiveness of pharmacotherapy in treating children with AMPS. However, the data available in adult populations provide minimal support for pharmacotherapy as a successful treatment for amplified pain, with some explicitly denying the effectiveness of specific drugs examined here [11] [12] [26] [27] [28] [29] [30] . When children are diagnosed with AMPS in our clinic, all medications related to pain and sleep are discontinued, with few exceptions. Additionally, the use of any aids is strongly discouraged and we do not use procedures such as blocks. We also discourage visits to other health care providers with the exception of physical therapists, occupational therapists, and psychotherapists, who treat focused on function rather than pain, as described in studies that have shown benefit [24] [25] [31] [32] [33] [34] . The increasing trend in medicalization of this population is especially alarming when considering the increased risk borne by these children without established evidence of benefit. Reported untoward effects from medical treatment of amplified pain is legion [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] .
Over the first few years examined in our study, there was a significantly increasing percentage of children with diffuse AMPS, but this has leveled off over the last 3 years, without a concomitant leveling of medicalization. Medications, studies, therapies, seen professionals, procedures, hospitalizations, and surgeries are all significantly increased. In the same population, there were no significant changes in patient reported pain score, pain duration, or disability. We postulate that the increased medicalization is both patient/family driven and health care provider driven. These children have severe chronic pain and disability, perhaps making the families more open to trying unproven remedies. We speculate that many families seek out newer treatments and health care providers over the Internet, including self-referrals to our clinic. Likewise, when a new medicine or therapy is available, physicians, who are either pressured by the family or by their own therapy philosophy to try anything to give quick, medicinal relief, will prescribe medicines of unproven benefit. This may explain, in part, the increase of patients being prescribed pregabalin, even though it is not approved for use in children. Metaanalyses in adults show increased effectiveness compared to placebo but significant side effects, such as dizziness, peripheral edema, and weight gain [26] [27] [28] . These side effects were shown to cause one in four adults taking pregabalin to cease treatment [27] . The very recent increased use of pharmacotherapy not approved for use in children seen here is noteworthy. This significant increase in medication use may also be due to the dramatic increase in the number of professionals seen, as increased doctor's visits may result in increased pharmacotherapies tried, in addition to increased studies and procedures performed.
The use of aids, such as boots, crutches, and wheelchairs, did not change over time. When considering the unchanged degree of disability or patient pain level by year and the lack of newly available types of aids, one would not expect increased use of these methods for pain relief. Additionally, the increase in children with diffuse pain rather than pain in one body part may also, in part, explain this, as one would not expect an increase in crutches if more children present with total body pain. However, there was also no increase in the use of wheelchairs. This suggests that the lack in novel aids available could be a primary cause for limited increase in use over time.
Limitations
Although the upwards trends seen here are noteworthy, this study is not without its limitations. All medicalization data were based upon self-reported histories, creating the potential for bias. This self-report method may have produced inaccuracies in the amount and type of treatments or medications tried, but could have also led to an under-reporting of more alternative therapies. Additionally, the method of reporting patient history could have improved over the 6-year chart review time period, causing a perceived increase in medicalization where there is simply an improvement in reporting. However, all questions about past medicalization present in the 2014 charts were also present in the 2008 charts. The consistency of pain history prompts should offset improvements in reporting.
These data also only encompass patients with AMPS evaluated at a single tertiary hospital with a clinic that specializes in the identification and treatment of children with chronic musculoskeletal pain. This clinic also advocates for decreased use of medications for treating chronic pain. Ideally, this study would include analyses from other pain programs. Additionally, our survey is only proxy for the cost of care, and a further analysis of the healthcare costs to both society and families is warranted. Future research examining the effects of medicalization on long-term outcomes in the pediatric pain population is also warranted.
Conclusion
Children with chronic musculoskeletal pain are becoming increasingly medicalized. The significant increase in medicalization of children with AMPS is not related to an increase in patient reported pain, which is evidenced by the lack of significant increase in patients' pain score, pain duration, or functional disability at the time of their initial evaluation.
